Genentech’s Phase III study of Avastin (bevacizumab) plus chemotherapy, followed by maintenance use of Avastin alone, increased progression-free survival (PFS) in women with previously untreated advanced ovarian cancer, compared to chemotherapy alone. In the three-arm study called Gynecologic Oncology Group (GOG) 0218, women with newly diagnosed advanced ovarian cancer were randomized to receive one of the following: placebo in combination with carboplatin and paclitaxel chemotherapy followe...